Sign In / Join

favorite Donate

close

person Sign In / Create Account

HealthTree News

HealthTree News is a place to learn all about your disease in easy-to-understand language. The site features news articles, patient stories, basics articles, and clinical trial updates with new content every week.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

When is Medicare Considered Your Secondary Insurance?

Jul. 25, 2024

When is Medicare Considered Your Secondary Insurance?

EHA 2024: Bispecific Antibodies and New Advances in Myeloma Treatment with Dr. Ola Landgren

Jul. 24, 2024

EHA 2024: Bispecific Antibodies and New Advances in Myeloma Treatment with Dr. Ola Landgren

What Is Nonsecretory Multiple Myeloma?

Jul. 22, 2024

What Is Nonsecretory Multiple Myeloma?

What’s Genetic Testing in Multiple Myeloma?

Jul. 22, 2024

What’s Genetic Testing in Multiple Myeloma?

Monitoring Minimal Residual Disease in Blood with EasyM

Jul. 19, 2024

Monitoring Minimal Residual Disease in Blood with EasyM

Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring

Jul. 18, 2024

Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring

Is MRD Negativity the Goal of Myeloma Treatment?

Jul. 18, 2024

Is MRD Negativity the Goal of Myeloma Treatment?

Real-World CAR T Data for Extramedullary Patients

Jul. 17, 2024

Real-World CAR T Data for Extramedullary Patients

HealthTree Foundation Featured on ABC News

Jul. 16, 2024

HealthTree Foundation Featured on ABC News

Smoldering Myeloma: What We Know And Where We’re Going

Jul. 16, 2024

Smoldering Myeloma: What We Know And Where We’re Going

Jack Aiello, Myeloma Advocate Extraordinaire

Jul. 15, 2024

Jack Aiello, Myeloma Advocate Extraordinaire

WoMMen Trekking Peru Starts Today

Jul. 12, 2024

WoMMen Trekking Peru Starts Today

Recent Articles

ASCO 2024: The More the Better in Newly Diagnosed Multiple Myeloma image

ASCO 2024: The More the Better in Newly Diagnosed Multiple Myeloma

July 10, 2024

Four-drug combinations beat three-drug combinations for newly diagnosed myeloma patients, achieving higher MRD-negative rates regardless of fitness status.

Why is Multiple Myeloma So Complicated? image

Why is Multiple Myeloma So Complicated?

July 09, 2024

Multiple myeloma is complicated due to its heterogeneity, location in the bone marrow, and clinical presentation of the cancer. Understand myeloma better today.

Diagnosed With High-Risk Myeloma, What Now? image

Diagnosed With High-Risk Myeloma, What Now?

July 08, 2024

Learn with Dr. Dima about what does it mean to have high-risk myeloma and the implication for you and your treatment options, and current research.

Treatment Advances

Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring image

Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring

Real-World CAR T Data for Extramedullary Patients image

Real-World CAR T Data for Extramedullary Patients

Smoldering Myeloma: What We Know And Where We’re Going image

Smoldering Myeloma: What We Know And Where We’re Going

CHIP and Multiple Myeloma: Impact on Stem Cell Transplant & Survival Rates image

CHIP and Multiple Myeloma: Impact on Stem Cell Transplant & Survival Rates

Can AI Detect MGUS Progression With Our Fat Cells? image

Can AI Detect MGUS Progression With Our Fat Cells?

MRD as a Clinical Trial Endpoint: A Patient Perspective image

MRD as a Clinical Trial Endpoint: A Patient Perspective

Load More

Core Education

Why is Multiple Myeloma So Complicated? image

Why is Multiple Myeloma So Complicated?

What Is A Chemo Port? image

What Is A Chemo Port?

Proteasome Inhibitors: Still a Powerful Weapon Against Myeloma image

Proteasome Inhibitors: Still a Powerful Weapon Against Myeloma

What are Relapsed and Refractory Myeloma? image

What are Relapsed and Refractory Myeloma?

What are Antibodies and How are They Used in Multiple Myeloma? image

What are Antibodies and How are They Used in Multiple Myeloma?

What Is MRD Testing? image

What Is MRD Testing?

Load More

Trending Articles

Jack Aiello, Myeloma Advocate Extraordinaire

Jack Aiello, Myeloma Advocate Extraordinaire

Is MRD Negativity the Goal of Myeloma Treatment?

Is MRD Negativity the Goal of Myeloma Treatment?

Smoldering Myeloma: What We Know And Where We’re Going

Smoldering Myeloma: What We Know And Where We’re Going

Real-World CAR T Data for Extramedullary Patients

Real-World CAR T Data for Extramedullary Patients

Why is Multiple Myeloma So Complicated?

Why is Multiple Myeloma So Complicated?

Upcoming Events

Understanding MGUS, Its Progression Risks, and More

Understanding MGUS, Its Progression Risks, and More

Aug 15 / 13:00 EDT

Virtual Black Myeloma Health Movement Awareness Event 2024

Virtual Black Myeloma Health Movement Awareness Event 2024

Aug 17 / 0:00 EDT

Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.

Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.

Aug 20 / 18:00 EDT

Patient Stories

articles for Patient Stories

Jack Aiello, Myeloma Advocate Extraordinaire Celebrating Two Decades with Multiple Myeloma: Vicki Jones’ Journey Read Stacey’s Myeloma Story & Meet Her at the HealthTree 5K/1M!

HealthTree Research

articles for HealthTree Research

WoMMen Trekking Peru Starts Today Taking Myeloma Research to New Heights in Peru ASCO 2024: HealthTree’s Collaboration on The Role of Dietary Supplements in Cancer Patient Care

Conferences

articles for Conferences

EHA 2024: Bispecific Antibodies and New Advances in Myeloma Treatment with Dr. Ola Landgren ASCO 2024: The More the Better in Newly Diagnosed Multiple Myeloma ASCO 2024: BCMA-Directed Therapies in Relapsed Multiple Myeloma

Clinical Trials

articles for Clinical Trials

First R/R Myeloma Patient Treated with New BCMA-Directed Bispecific Antibody in Phase 3 Study The Use of Bispecifics and CAR-T in Myeloma Treatment Ensuring Access to Myeloma Research, with Dr. Gurbakhash Kaur

HealthTree Press

articles for HealthTree Press

HealthTree Foundation Featured on ABC News HealthTree Foundation Announces Launch of HealthTree Research Hub in Multiple Myeloma Announcing the Launch of HealthTree 2.0 on October 23rd

HealthTree Programs

articles for HealthTree Programs

What’s Genetic Testing in Multiple Myeloma? Is MRD Negativity the Goal of Myeloma Treatment? Join Us for the October Detroit Roundtable for Multiple Myeloma

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Regeneron

Bristol Myers Squibb

Follow Us

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2024 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811